XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

NCT00365352 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

325

Enrollment

INDUSTRY

Sponsor class

Conditions

Restless Legs Syndrome

Interventions

DRUG: XP13512 600MG
DRUG: XP13512 1200MG
DRUG: PLACEBO

Sponsor

XenoPort, Inc.